After living-donor liver transplant, a 30% to 50% lower starting dose of tacrolimus is reasonable

Design

Systematic critical review of pharmacokinetic studies (PubMed, March 2025)

Population

Children and adults after living-donor liver transplantation; 8 tacrolimus and 8 mycophenolate studies

Primary outcome

Initial dosing recommendations for tacrolimus and mycophenolate

Effect

Tacrolimus starting dose 30% to 50% lower than after deceased-donor transplant; mycophenolate unchanged

This systematic critical review (published in May) asked how to start tacrolimus and mycophenolate after living-donor liver transplantation (LDLT), where a smaller graft and liver regeneration are expected to change drug handling. It identified eight pharmacokinetic studies of immediate-release tacrolimus and eight of mycophenolate in children or adults, from a PubMed search in March 2025.

The literature suggests that LDLT recipients need lower tacrolimus doses than deceased-donor recipients, particularly early after transplant, and that CYP3A5 polymorphisms in both donor and recipient add variability in exposure. Evidence on mycophenolate is limited, with too little to support dose reduction. The authors conclude that starting tacrolimus 30% to 50% lower than in deceased-donor transplantation would be reasonable, with the mycophenolate dose unchanged.

This is a small review of mostly observational pharmacokinetic studies, and the search was limited to PubMed. The recommendation is a starting point, and it does not replace trough monitoring, which must guide subsequent doses. Local protocols and CYP3A5 genotyping availability should shape how it is used.

• Consider a lower initial tacrolimus dose (the review suggests 30% to 50% lower) after living-donor than deceased-donor liver transplantation.
• Follow trough levels closely in the early period and adjust to them.
• Keep the initial mycophenolate dose the same; evidence for reducing it is limited.
• Remember that donor and recipient CYP3A5 genotype can alter exposure.

Why it matters

A standard starting dose can overexpose a patient with a smaller regenerating liver.

Don't overread it

The recommendation rests on eight small pharmacokinetic studies and is a starting point that must be checked against trough levels.

The statistics, in plain English

'30% to 50% lower' is a range from a handful of small studies rather than a measured optimum. It tells you the direction and rough size of the adjustment, not the exact dose for a patient.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.